Educated Patient® Multiple Myeloma Summit: March 13, 2021

Updated NCCN guidelines for multiple myeloma add dedicated recommendations for MRD testing, prefer tests that can detect one cancer cell among 1 million cells and expand when testing should occur.

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.

Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.

WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung cancer. Here's what patients should know about three key studies.